Ryvu Therapeutics

• Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma

  Collaborator, Phase 1, Not yet recruiting, 48 people, 8 Oct 2026

• NCT06987058

  Phase 2, Enrolling by invitation, 14 people, 23 May 2025

• NCT06397313

  Phase 2, Terminated, 36 people, 2 May 2024

• NCT06191263

  Phase 2, Recruiting, 98 people, 5 Jan 2024

Sources: clinicaltrials.gov

• Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

  Shares or equity, 12 Jan 2026

Sources: pubmed.ncbi.nlm.nih.gov